Breast cancer-associated metastasis is significantly increased in a model of autoimmune arthritis

Breast Cancer Research

Volumn 11, Issue 4, 2009, Pages

  Das Roy, Lopamudra ^a,b   Pathangey, Latha B ^a   Tinder, Teresa L ^a,b   Schettini, Jorge L ^a,b   Gruber, Helen E ^c   Mukherjee, Pinku ^a,b  

^a MAYO GRADUATE SCHOOL   (United States)

^b UNIVERSITY OF NORTH CAROLINA AT CHARLOTTE   (United States)

^c CAROLINAS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELECOXIB; COLONY STIMULATING FACTOR 1; INTERLEUKIN 17; INTERLEUKIN 17 ANTIBODY; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; CYTOKINE; MONOCLONAL ANTIBODY; NONSTEROID ANTIINFLAMMATORY AGENT; PROTEIN KINASE ZAP 70; PTGS2 PROTEIN, MOUSE; PYRAZOLE DERIVATIVE; SULFONAMIDE; ZAP70 PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTHRITIS; ARTICLE; AUTOIMMUNE ARTHRITIS; AUTOIMMUNE DISEASE; BONE DESTRUCTION; BONE METASTASIS; BREAST CANCER; CANCER LOCALIZATION; CELL INFILTRATION; CHRONIC INFLAMMATION; CONTROLLED STUDY; DISEASE SEVERITY; GRANULOCYTE; HUMAN; HUMAN CELL; LUNG METASTASIS; MAMMARY GLAND; MOUSE; MOUSE STRAIN; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PROTEIN BLOOD LEVEL; TUMOR CELL; ANIMAL; ANTIBODY SPECIFICITY; BAGG ALBINO MOUSE; BLOOD; BONE TUMOR; CHEMICALLY INDUCED DISORDER; DISEASE MODEL; DRUG ANTAGONISM; EXPERIMENTAL NEOPLASM; FEMALE; GENETICS; IMMUNOLOGY; LUNG LAVAGE; LUNG TUMOR; METASTASIS; MOUSE MUTANT; OSTEOCLAST; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; SECRETION; TRANSPLANTATION; TUMOR CELL LINE;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES, MONOCLONAL; ARTHRITIS; AUTOIMMUNE DISEASES; BONE NEOPLASMS; BRONCHOALVEOLAR LAVAGE FLUID; CELL LINE, TUMOR; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYTOKINES; DISEASE MODELS, ANIMAL; FEMALE; INTERLEUKIN-17; LUNG NEOPLASMS; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED BALB C; MICE, MUTANT STRAINS; NEOPLASM METASTASIS; ORGAN SPECIFICITY; OSTEOCLASTS; PYRAZOLES; SULFONAMIDES; ZAP-70 PROTEIN-TYROSINE KINASE;

EID: 77449137980     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr2345     Document Type: Article

References (51)

1. de Visser KE, Coussens LM. The inflammatory tumor microenvironment and its impact on cancer development. Contrib Microbiol 2006, 13:118-137. full_text, 16627962.
2. Ziegler J. Cancer and arthritis share underlying processes. J Natl Cancer Inst 1998, 90:802-803. 10.1093/jnci/90.11.802, 9625164.
3. Franklin J, Lunt M, Bunn D, Symmons D, Silman A. Influence of inflammatory polyarthritis on cancer incidence and survival: results from a community-based prospective study. Arthritis Rheum 2007, 56:790-798. 10.1002/art.22430, 17328051.
4. Mellemkjaer L, Linet MS, Gridley G, Frisch M, Moller H, Olsen JH. [Rheumatoid arthritis and risk of cancer]. Ugeskr Laeger 1998, 160:3069-3073.
5. Askling J, Fored CM, Baecklund E, Brandt L, Backlin C, Ekbom A, Sundstrom C, Bertilsson L, Coster L, Geborek P, Jacobsson LT, Lindblad S, Lysholm J, Rantapää-Dahlqvist S, Saxne T, Klareskog L, Feltelius N. Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists. Ann Rheum Dis 2005, 64:1414-1420. 10.1136/ard.2004.033241, 1755232, 15843454.
6. Askling J, Fored CM, Brandt L, Baecklund E, Bertilsson L, Feltelius N, Coster L, Geborek P, Jacobsson LT, Lindblad S, Lysholm J, Rantapää-Dahlqvist S, Saxne T, Klareskog L. Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists. Ann Rheum Dis 2005, 64:1421-1426. 10.1136/ard.2004.033993, 1755244, 15829572.
7. Minn AJ, Gupta GP, Siegel PM, Bos PD, Shu W, Giri DD, Viale A, Olshen AB, Gerald WL, Massague J. Genes that mediate breast cancer metastasis to lung. Nature 2005, 436:518-524. 10.1038/nature03799, 1283098, 16049480.
8. Mundy GR. Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer 2002, 2:584-593. 10.1038/nrc867, 12154351.
9. Sakaguchi N, Takahashi T, Hata H, Nomura T, Tagami T, Yamazaki S, Sakihama T, Matsutani T, Negishi I, Nakatsuru S, Sakaguchi S. Altered thymic T-cell selection due to a mutation of the ZAP-70 gene causes autoimmune arthritis in mice. Nature 2003, 426:454-460. 10.1038/nature02119, 14647385.
10. Hata H, Sakaguchi N, Yoshitomi H, Iwakura Y, Sekikawa K, Azuma Y, Kanai C, Moriizumi E, Nomura T, Nakamura T, Sakaguchi S. Distinct contribution of IL-6, TNF-alpha, IL-1, and IL-10 to T cell-mediated spontaneous autoimmune arthritis in mice. J Clin Invest 2004, 114:582-588. 503774, 15314695.
11. Firestein GS. Evolving concepts of rheumatoid arthritis. Nature 2003, 423:356-361. 10.1038/nature01661, 12748655.
12. Yoshitomi H, Sakaguchi N, Kobayashi K, Brown GD, Tagami T, Sakihama T, Hirota K, Tanaka S, Nomura T, Miki I, Gordon S, Akira S, Nakamura T, Sakaguchi S. A role for fungal {beta}-glucans and their receptor Dectin-1 in the induction of autoimmune arthritis in genetically susceptible mice. J Exp Med 2005, 201:949-960. 10.1084/jem.20041758, 2213107, 15781585.
13. Woo MK, Nordal RA. Commissioning and evaluation of a new commercial small rodent x-ray irradiator. Biomed Imaging Interv J 2006, 2(1):e10. 10.2349/biij.2.1.e10.
14. Hattrup CL, Gendler SJ. MUC1 alters oncogenic events and transcription in human breast cancer cells. Breast Cancer Res 2006, 8:R37. 10.1186/bcr1515, 1779460, 16846534.
15. Raman D, Baugher PJ, Thu YM, Richmond A. Role of chemokines in tumor growth. Cancer Lett 2007, 256:137-165. 10.1016/j.canlet.2007.05.013, 17629396, 2065851.
16. Basu GD, Pathangey LB, Tinder TL, LaGioia M, Gendler SJ, Mukherjee P. COX-2 inhibitor induces apoptosis in breast cancer cells in an in vivo model of spontaneous metastatic breast cancer. Mol Cancer Res 2004, 2:632-642.
17. Rask K, Zhu Y, Wang W, Hedin L, Sundfeldt K. Ovarian epithelial cancer: a role for PGE2-synthesis and signalling in malignant transformation and progression. Mol Cancer 2006, 5:62-66. 10.1186/1476-4598-5-62, 1657027, 17107625.
18. Hu M, Peluffo G, Chen H, Gelman R, Schnitt S, Polyak K. Role of COX-2 in epithelial-stromal cell interactions and progression of ductal carcinoma in situ of the breast. Proc Natl Acad Sci USA 2009, 106:3372-3377. 10.1073/pnas.0813306106, 2642666,2642666, 19218449.
19. Roodman GD. Mechanisms of bone metastasis. N Engl J Med 2004, 350:1655-1664. 10.1056/NEJMra030831, 15084698.
20. Kryczek I, Wei S, Zou L, Altuwaijri S, Szeliga W, Kolls J, Chang A, Zou W. Cutting edge: Th17 and regulatory T cell dynamics and the regulation by IL-2 in the tumor microenvironment. J Immunol 2007, 178:6730-6733.
21. Jin D, Zhang L, Zheng J, Zhao Y. The inflammatory Th 17 subset in immunity against self and non-self antigens. Autoimmunity 2008, 41:154-162. 10.1080/08916930701776605, 18324485.
22. Stanislaw MS, Wenhao C. Functional quartet by CD4+ T cells: a concerto of multiple cytokines. Expert Rev Clin Immunol 2008, 4:5-7.
23. Kaiko GE, Horvat JC, Beagley KW, Hansbro PM. Immunological decision-making: how does the immune system decide to mount a helper T-cell response?. Immunology 2008, 123:326-338. 10.1111/j.1365-2567.2007.02719.x, 2433332, 17983439.
24. Kotake S, Udagawa N, Takahashi N, Matsuzaki K, Itoh K, Ishiyama S, Saito S, Inoue K, Kamatani N, Gillespie MT, Martin TJ, Suda T. IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis. J Clin Invest 1999, 103:1345-1352. 10.1172/JCI5703, 408356, 10225978.
25. Tsujisawa T, Inoue H, Nishihara T. SC-1 antagonist of prostaglandin E2 receptor EP1, inhibits osteoclastogenesis by RANKL. J Bone Miner Res 9220, 20:15-22. 15619665.
26. Juarranz Y, Abad C, Martinez C, Arranz A, Gutierrez-Canas I, Rosignoli F, Gomariz RP, Leceta J. Protective effect of vasoactive intestinal peptide on bone destruction in the collagen-induced arthritis model of rheumatoid arthritis. Arthritis Res Ther 2005, 7:R1034-1045. 10.1186/ar1779, 1257432, 16207319.
27. Arun B, Goss P. The role of COX-2 inhibition in breast cancer treatment and prevention. Semin Oncol 2004, 31(2 Suppl 7):22-29. 10.1053/j.seminoncol.2004.03.042, 15179621.
28. Harris RE, Beebe-Donk J, Alshafie GA. Reduction in the risk of human breast cancer by selective cyclooxygenase-2 (COX-2) inhibitors. BMC Cancer 2006, 6:27. 10.1186/1471-2407-6-27, 1373658, 16445867.
29. Slattery MJ, Liang S, Dong C. Distinct role of hydrodynamic shear in leukocyte-facilitated tumor cell extravasation. Am J Physiol Cell Physiol 2005, 288:C831-839. 10.1152/ajpcell.00439.2004, 15601752.
30. Sakaguchi S, Sakaguchi N. Regulatory T cells in immunologic self-tolerance and autoimmune disease. Int Rev Immunol 2005, 24:211-226. 10.1080/08830180590934976, 16036375.
31. Arend WP, Dayer JM. Inhibition of the production and effects of interleukin-1 and tumor necrosis factor alpha in rheumatoid arthritis. Arthritis Rheum 1995, 38:151-160. 10.1002/art.1780380202, 7848304.
32. Curry JM, Eubank TD, Roberts RD, Wang Y, Pore N, Maity A, Marsh CB. M-CSF signals through the MAPK/ERK pathway via Sp1 to induce VEGF production and induces angiogenesis in vivo. PLoS One 2008, 3:3405-3411. 18852899, 10.1371/journal.pone.0003405.
33. Toy EP, Azodi M, Folk NL, Zito CM, Zeiss CJ, Chambers SK. Enhanced ovarian cancer tumorigenesis and metastasis by the macrophage colony-stimulating factor. Neoplasia 2009, 11:136-144. 2631138, 19177198.
34. Leitzel K, Ettenberg S, Walsh R, Abraham J, Modur V, Braendle E, Evans DB, Ali SM, Demers L, Lipton A. Elevated serum M-CSF level predicts reduced survival in metastatic breast cancer patients. J Clin Oncology 2007, 25:10591-10599.
35. Lyon DE, McCain NL, Walter J, Schubert C. Cytokine comparisons between women with breast cancer and women with a negative breast biopsy. Nurs Res 2008, 57:51-58. 10.1097/01.NNR.0000280655.58266.6c, 18091292, 2234268.
36. Nam JS, Terabe M, Kang MJ, Chae H, Voong N, Yang YA, Laurence A, Michalowska A, Mamura M, Lonning S, Berzofsky JA, Wakefield LM. Transforming growth factor beta subverts the immune system into directly promoting tumor growth through interleukin-17. Cancer Res 2008, 68:3915-3923. 10.1158/0008-5472.CAN-08-0206, 2586596, 18483277.
37. Zhu X, Mulcahy LA, Mohammed RA, Lee AH, Franks HA, Kilpatrick L, Yilmazer A, Paish EC, Ellis IO, Patel PM, Jackson AM. IL-17 expression by breast-cancer-associated macrophages: IL-17 promotes invasiveness of breast cancer cell lines. Breast Cancer Res 2008, 10:R95. 10.1186/bcr2195, 2656888, 19014637.
38. Ben-Baruch A. Inflammation-associated immune suppression in cancer: the roles played by cytokines, chemokines and additional mediators. Semin Cancer Biol 2006, 16:38-52. 10.1016/j.semcancer.2005.07.006, 16139507.
39. Sansone P, Storci G, Tavolari S, Guarnieri T, Giovannini C, Taffurelli M, Ceccarelli C, Santini D, Paterini P, Marcu KB, Cheico P, Bonafe M. IL-6 triggers malignant features in mammospheres from human ductal breast carcinoma and normal mammary gland. J Clin Invest 2007, 117:3988-4002. 10.1172/JCI32533, 2096439, 18060036.
40. Leek RD, Harris AL. Tumor-associated macrophages in breast cancer. J Mammary Gland Biol Neoplasia 2002, 7:177-189. 10.1023/A:1020304003704, 12463738.
41. Kulbe H, Thompson R, Wilson JL, Robinson S, Hagemann T, Fatah R, Gould D, Ayhan A, Balkwill F. The inflammatory cytokine tumor necrosis factor-alpha generates an autocrine tumor-promoting network in epithelial ovarian cancer cells. Cancer Res 2007, 67:585-592. 10.1158/0008-5472.CAN-06-2941, 2679985, 17234767.
42. Loges S, Mazzone M, Hohensinner P, Carmeliet P. Silencing or fueling metastasis with VEGF inhibitors: antiangiogenesis revisited. Cancer Cell 2009, 15:167-170. 10.1016/j.ccr.2009.02.007, 19249675.
43. Chan A. Antiangiogenic therapy for metastatic breast cancer: current status and future directions. Drugs 2009, 69:167-181. 10.2165/00003495-200969020-00003, 19228074.
44. Byrnes K, White S, Chu Q, Meschonat C, Yu H, Johnson LW, Debenedetti A, Abreo F, Turnage RH, McDonald JC, Li BD. High eIF4E, VEGF, and microvessel density in stage I to III breast cancer. Ann Surg 2006, 243:684-690. 10.1097/01.sla.0000216770.23642.d8, 1570543, 16633004.
45. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002, 420:860-867. 10.1038/nature01322, 12490959.
46. Philip M, Rowley DA, Schreiber H. Inflammation as a tumor promoter in cancer induction. Semin Cancer Biol 2004, 14:433-439. 10.1016/j.semcancer.2004.06.006, 15489136.
47. Clevers H. At the crossroads of inflammation and cancer. Cell 2004, 118:671-674. 10.1016/j.cell.2004.09.005, 15369667.
48. Balkwill F, Charles KA, Mantovani A. Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell 2005, 7:211-217. 10.1016/j.ccr.2005.02.013, 15766659.
49. Gout S, Huot J. Role of cancer microenvironment in metastasis: focus on colon cancer. Cancer Microenviron 2008, 1:69-83. 10.1007/s12307-008-0007-2, 2654352, 19308686.
50. Mukherjee P, Madsen CS, Ginardi AR, Tinder TL, Jacobs F, Parker J, Agrawal B, Longenecker BM, Gendler SJ. Mucin 1-specific immunotherapy in a mouse model of spontaneous breast cancer. J Immunother 2003, 26:47-62. 10.1097/00002371-200301000-00006, 12514429.
51. Brand DD, Latham KA, Rosloniec EF. Collagen-induced arthritis. Nat Protoc 2007, 2:1269-1275. 10.1038/nprot.2007.173, 17546023.